Active NSCLC Clinical Trials

Data from ClinicalTrials.gov · Privacy-First Design · No Account Required · No Health Data Stored

Why Consider a Non-Small Cell Lung Cancer (NSCLC) Clinical Trial?

• Find Trials That Fit — Browse recruiting Non-Small Cell Lung Cancer (NSCLC) trials pulled directly from ClinicalTrials.gov — updated continuously so you always see real, active studies.
• No Medical Jargon — Eligibility criteria are rewritten into plain yes-or-no questions. It's always okay to answer "not sure" — your doctor can help fill in the rest.
• See How Well You Match — Get a clear picture of how closely a trial fits your situation, so you know which ones are worth bringing to your oncologist.
• Ready for Your Appointment — Generate a printable or emailable summary for your next visit. A caregiver can send it to your doctor ahead of time.

How It Works

1. Share a Few Details — Enter your Non-Small Cell Lung Cancer (NSCLC) type, stage, and location. No personal health information is required or stored.
2. Answer Yes-or-No Questions — We rewrite complex eligibility criteria into plain language. "Not sure" is always a valid answer.
3. Bring Results to Your Doctor — Get a printable summary with the NCT ID, match assessment, and questions to ask your oncologist.

Free · No account · Nothing you enter is stored

Non-Small Cell Lung Cancer (NSCLC) Clinical Trial FAQ

What biomarker tests should I have before looking for an NSCLC clinical trial?

Comprehensive molecular profiling (next-generation sequencing) is strongly recommended for all advanced NSCLC patients. Key targets include EGFR (exon 19 del, L858R, exon 20 ins), ALK, ROS1, KRAS G12C, MET exon 14 skipping, RET fusions, BRAF V600E, NTRK fusions, and HER2. PD-L1 expression by IHC is also standard. Together, these results determine which targeted therapy or immunotherapy trials you qualify for.

Are there NSCLC trials for patients with EGFR mutations?

Yes — EGFR-mutated NSCLC is one of the most active trial areas in oncology. Trials are testing third-generation EGFR inhibitors (osimertinib combinations and variants), novel agents for uncommon EGFR mutations (exon 20 insertions, G719X, L861Q), and strategies to overcome acquired resistance (C797S, MET amplification). Knowing your specific EGFR variant helps narrow down the most relevant studies.

Can NSCLC patients with ALK or ROS1 rearrangements join clinical trials?

Yes. While lorlatinib and other approved ALK inhibitors are effective, resistance eventually develops. Trials are testing next-generation ALK inhibitors, combination approaches, and strategies targeting specific ALK resistance mutations. ROS1-rearranged NSCLC trials are testing entrectinib variants and next-generation ROS1 inhibitors like repotrectinib.

What is the difference between first-line, second-line, and later-line NSCLC trials?

First-line trials enroll patients who have not received any prior systemic treatment for metastatic NSCLC. Second-line trials enroll patients whose cancer progressed on one prior line of therapy. Later-line trials are for patients who have already received two or more treatments. Some adjuvant trials also enroll patients after surgery or radiation. Your prior treatment history is one of the first eligibility questions Trialify asks.

How do I find an NSCLC trial that matches my mutation profile?

Enter your cancer type, specific mutation (e.g., EGFR L858R, ALK fusion), line of therapy, and ZIP code on Trialify. We search ClinicalTrials.gov and translate the eligibility criteria into plain language. You get a match score and a printable doctor summary to bring to your next oncology appointment — no account required.

Explore Other Cancer Trial Guides

• Lung Cancer — Lung cancer is the leading cause of cancer-related death worldwide. Recruiting clinical trials are testing new immunotherapies, targeted therapies, and combination regimens for NSCLC and SCLC patients.
• Small Cell Lung Cancer (SCLC) — Small cell lung cancer (SCLC) is a fast-growing form of lung cancer that accounts for roughly 15% of lung cancer cases. New trials are testing immunotherapy combinations, antibody-drug conjugates (DLL3-targeting agents), and novel mechanisms for both limited- and extensive-stage disease.
• KRAS-Mutated Lung Cancer — KRAS mutations are the most common oncogenic driver in NSCLC, found in approximately 25–30% of adenocarcinomas. Sotorasib and adagrasib are approved for KRAS G12C, and next-generation KRAS inhibitors targeting G12D, G12V, and pan-KRAS are in active clinical trials.
• Head and Neck Cancer — Head and neck cancer trials are testing PD-1/PD-L1 checkpoint inhibitors, cetuximab combinations, and organ-preservation strategies for squamous cell carcinoma of the oral cavity, oropharynx, larynx, and hypopharynx.